A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
66
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Uveal Melanoma
Interventions
DRUG:
DYP688
Sponsor
Novartis Pharmaceuticals